109 related articles for article (PubMed ID: 34610216)
21. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
22. CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling.
Lai CJ; Lin CY; Liao WY; Hour TC; Wang HD; Chuu CP
Cells; 2019 Mar; 8(4):. PubMed ID: 30935014
[TBL] [Abstract][Full Text] [Related]
23. Histone Deacetylase Inhibitors Enhance Cytotoxicity Towards Breast Tumors While Preserving the Wound-Healing Function of Adipose-Derived Stem Cells.
Koko KR; Chang S; Hagaman AL; Fromer MW; Nolan RS; Gaughan JP; Zhang P; Carpenter JP; Brown SA; Matthews M; Bird D
Ann Plast Surg; 2017 Jun; 78(6):728-735. PubMed ID: 28489652
[TBL] [Abstract][Full Text] [Related]
24. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
25. ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.
Yu D; Zhong Y; Li X; Li Y; Li X; Cao J; Fan H; Yuan Y; Ji Z; Qiao B; Wen JG; Zhang M; Kvalheim G; Nesland JM; Suo Z
Oncotarget; 2015 Dec; 6(40):42687-703. PubMed ID: 26528857
[TBL] [Abstract][Full Text] [Related]
26. Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.
Li D; Zhao LN; Zheng XL; Lin P; Lin F; Li Y; Zou HF; Cui RJ; Chen H; Yu XG
Mol Med Rep; 2014 Dec; 10(6):3169-76. PubMed ID: 25310235
[TBL] [Abstract][Full Text] [Related]
27. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
[TBL] [Abstract][Full Text] [Related]
28. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.
Fujita Y; Kojima K; Ohhashi R; Hamada N; Nozawa Y; Kitamoto A; Sato A; Kondo S; Kojima T; Deguchi T; Ito M
J Biol Chem; 2010 Jun; 285(25):19076-84. PubMed ID: 20406806
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
Zhang M; Mukherjee N; Bermudez RS; Latham DE; Delaney MA; Zietman AL; Shipley WU; Chakravarti A
Prostate; 2005 Aug; 64(3):293-302. PubMed ID: 15754318
[TBL] [Abstract][Full Text] [Related]
30. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
[TBL] [Abstract][Full Text] [Related]
31. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells.
Saari H; Lázaro-Ibáñez E; Viitala T; Vuorimaa-Laukkanen E; Siljander P; Yliperttula M
J Control Release; 2015 Dec; 220(Pt B):727-37. PubMed ID: 26390807
[TBL] [Abstract][Full Text] [Related]
32. NANOG as prognostic factor of prostate cancer course.
Zadvornyi TV; Lukianova NY; Borikun TV; Vitruk YV; Stakhovsky EO; Chekhun VF
Exp Oncol; 2020 Jun; 42(2):94-100. PubMed ID: 32602285
[TBL] [Abstract][Full Text] [Related]
33. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
Kanwal R; Shukla S; Walker E; Gupta S
Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
[TBL] [Abstract][Full Text] [Related]
34. Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression.
Fan X; Chen X; Deng W; Zhong G; Cai Q; Lin T
BMC Cancer; 2013 Feb; 13():61. PubMed ID: 23383988
[TBL] [Abstract][Full Text] [Related]
35. Nanog-mediated stem cell properties are critical for MBNL3-associated paclitaxel resistance of ovarian cancer.
Sun X; Diao X; Zhu X; Yin X; Cheng G
J Biochem; 2021 Sep; 169(6):747-756. PubMed ID: 33599261
[TBL] [Abstract][Full Text] [Related]
36. Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Kikuno N; Moriyama-Gonda N; Yoshino T; Yoneda T; Urakami S; Terashima M; Yoshida M; Kishi H; Shigeno K; Shiina H; Igawa M
Cancer Res; 2004 Oct; 64(20):7526-32. PubMed ID: 15492279
[TBL] [Abstract][Full Text] [Related]
37. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
[TBL] [Abstract][Full Text] [Related]
38. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of ID-1 gene induces sensitivity of prostate cancer cells to chemotherapeutic drugs.
Wong YC; Zhang XM; Ling MT; Wang XH
Adv Exp Med Biol; 2008; 617():565-72. PubMed ID: 18497083
[TBL] [Abstract][Full Text] [Related]
40. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
